Moderna Due Diligence Report

Moderna is a commercial-stage biotechnology company whose mRNA platform produced Spikevax (the COVID-19 vaccine), and whose pipeline extends mRNA technology into respiratory vaccines (flu, RSV, COVID-flu combination), oncology (individualized neoantigen therapy with Merck), rare diseases (CRIG), and latent viruses (CMV, EBV, HIV). DoDiligence covers Moderna's post-pandemic respiratory-franchise economics, the mRNA platform optionality thesis, the Merck KEYNOTE-942 / mRNA-4157 oncology collaboration, manufacturing-cost reduction milestones, cash runway and capital allocation, and competitive positioning against BioNTech and traditional vaccine manufacturers.

What Our Moderna Diligence Report Covers

• Business Overview — Revenue model, key products/services, market position, and growth trajectory
• Financial Snapshot — Revenue, profitability margins, balance sheet health, and cash position
• Risk Flags — Regulatory exposure, litigation, customer concentration, and supply chain dependencies
• Competitive Landscape — Key competitors, market share dynamics, and competitive moats
• Management Assessment — Leadership track record, insider ownership, and governance quality
• Recent Developments — Latest news, product launches, M&A activity, and strategic shifts
• Diligence Score — Overall quantitative score (0-100) with component breakdowns

Full Report Also Includes

• Detailed 3-year financial analysis with trend projections
• Comparable transactions and precedent deal multiples
• Risk register with probability and impact ratings
• Regulatory and compliance deep-dive
• Investment committee workplan template